$3.91
0.13% today
NYSE, Jul 21, 05:15 pm CET
ISIN
US5019761049
Symbol
KYTX
Sector
Industry

Kyverna Therapeutics Stock price

$3.90
+0.99 34.02% 1M
+0.57 17.12% 6M
+0.16 4.28% YTD
-6.58 62.79% 1Y
-18.10 82.27% 3Y
-18.10 82.27% 5Y
-18.10 82.27% 10Y
-18.10 82.27% 20Y
NYSE, Closing price Fri, Jul 18 2025
-0.17 4.18%
ISIN
US5019761049
Symbol
KYTX
Sector
Industry

Key metrics

Basic
Market capitalization
$168.6m
Enterprise Value
$-73.5m
Net debt
positive
Cash
$242.7m
Shares outstanding
43.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.5
P/B
0.8
Financial Health
Equity Ratio
87.5%
Return on Equity
-47.6%
ROCE
-70.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-158.1m | $-191.6m
EBIT
$-160.2m | $-194.0m
Net Income
$-145.6m | $-161.0m
Free Cash Flow
$-134.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-77.2% | -36.0%
EBIT
-75.3% | -35.6%
Net Income
-66.7% | -26.8%
Free Cash Flow
-69.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.4
FCF per Share
$-3.1
Short interest
8.5%
Employees
112
Rev per Employee
$0.0
Show more

Is Kyverna Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,010 stocks worldwide.

Kyverna Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Kyverna Therapeutics forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Kyverna Therapeutics forecast:

Buy
92%
Hold
8%

Financial data from Kyverna Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 33 33
72% 72%
-
- Research and Development Expense 127 127
76% 76%
-
-158 -158
77% 77%
-
- Depreciation and Amortization 2.15 2.15
2% 2%
-
EBIT (Operating Income) EBIT -160 -160
75% 75%
-
Net Profit -146 -146
67% 67%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kyverna Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kyverna Therapeutics Stock News

Neutral
GlobeNewsWire
19 days ago
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on behalf of long-term stockholders following a class action complaint that was filed against Kyverna on December 9, 2024 with a Class Period pursuant and/or traceable to the Company's of...
Neutral
PRNewsWire
about 2 months ago
EMERYVILLE, Calif. , May 28, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 4, 2025, a...
Neutral
GlobeNewsWire
2 months ago
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on behalf of long-term stockholders following a class action complaint that was filed against Kyverna on December 9, 2024 with a Class Period pursuant and/or traceable to the Company's off...
More Kyverna Therapeutics News

Company Profile

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Head office United States
CEO Warner Biddle
Employees 112
Founded 2018
Website kyvernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today